EGLN3/PHD3 Antibody (700210) [Alexa Fluor® 594]

• Applications: ICC/IF
• Clone: 700210
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 594

EGLN3/PHD3 Antibody (700210) [Alexa Fluor® 594] Summary

• Immunogen: E. coli-derived recombinant human EGLN3/PHD3
  Pro2-Asp239
  Accession # Q9H6Z9
• Specificity: Detects human EGLN3/PHD3 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) EGLN1/PHD2 or rhEGLN2/PHD1 is observed.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Egl nine homolog 3 (EGLN3), also known as PHD3, is a widely expressed 27 kDa enzyme that hydroxylates proline residues on target proteins including HIF-1 alpha . HIF-1 is an alpha / beta heterodimeric transcriptional activator that upregulates genes involved in mitigating the effects of hypoxia. Normally, and in the presence of abundant oxygen, the HIF-1 alpha -chain is hydroxylated by PHD family members, which results in its ubiquitylation and degradation. Under low oxygen tension, EGLN3 activity is decreased, the HIF-1 alpha subunit is retained, and HIF-1 activates genes. EGLN3 also hydroxylates and promotes the degradation of the beta -2-adrenergic receptor, promotes myogenic differentiation, promotes apoptosis via caspase activation, and blocks tumor angiogenesis. EGLN3 forms homomultimers and heteromultimers with other EGLN proteins, and this is enhanced during hypoxia. EGLN3 contains one iron 2-oxoglutarate (Fe2OG) dioxygenase domain (aa 278-376), an iron-binding site (Asp 137 and His196), and a 2-oxoglutarate-binding site (Arg205). Within aa 2-239, human EGLN3 shares 97% aa sequence identity with mouse and rat EGLN3.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.